Saturday, September 5, 2026

Research Automation

2 articles

AI Systems Solve Complex Math Problems in Hours, Push Toward Automated Research Workflows

AI Systems Solve Complex Math Problems in Hours, Push Toward Automated Research Workflows

AI tools like Axiom Math's Axplorer now solve complex mathematical problems in hours on single machines, while OpenAI develops systems capable of working indefinitely like human researchers. The technology promises accelerated scientific breakthroughs, though experts note current limitations in generating truly novel research ideas.

LM Salvado
OpenAI CTO Says AI Research Labs Will Run Autonomously in Data Centers

OpenAI CTO Says AI Research Labs Will Run Autonomously in Data Centers

OpenAI's chief scientist predicts AI models will soon work indefinitely without human intervention, transforming research from code assistance to fully automated labs. The shift is driving infrastructure investment, with Palantir up 6% as the market splits between high-end training hardware and efficient inference workloads.

LM Salvado
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com